获得持续病毒学应答的慢性丙型肝炎患者发生肝细胞癌危险因素的研究进展

杨璐璇; 张新

doi:10.3969/j.issn.1001-5256.2017.03.033

获得持续病毒学应答的慢性丙型肝炎患者发生肝细胞癌危险因素的研究进展

DOI: 10.3969/j.issn.1001-5256.2017.03.033

杨璐璇,
张新

哈尔滨医科大学附属第一医院感染科

详细信息

中图分类号: R512.63;R735.7
计量
- 文章访问数: 2114
- HTML全文浏览量: 39
- PDF下载量: 425
- 被引次数: 0
出版历程
- 收稿日期: 2016-10-17
- 出版日期: 2017-03-20

Research advances in risk factors for hepatocellular carcinoma in chronic hepatitis C patients with sustained virologic response

Department of Infectious Diseases, The First Affiliated Hospital of Harbin Medical University

摘要

摘要: 目前普遍认为慢性丙型肝炎患者接受干扰素联合利巴韦林治疗方案获得持续病毒学应答等同于治愈,但临床上可观察到部分患者在获得持续病毒学应答后发生了肝细胞癌(HCC)。归纳并分析了近些年关于慢性丙型肝炎患者在获得持续病毒学应答后发生HCC的相关研究,总结了可能与HCC发生相关的危险因素。分析表明如男性、高龄、肝硬化、糖尿病等危险因素可能与HCC发生相关,但仍有为数不少的危险因素有待进一步研究。
- 肝炎,丙型,慢性 /
- 持续病毒学应答 /
- 癌,肝细胞 /
- 综述
Abstract: Nowadays it is generally believed that chronic hepatitis C patients who are treated with interferon combined with ribavirin and achieve sustained virologic response are considered cured, but in clinical practice, some patients develop hepatocellular carcinoma (HCC) after achieving sustained virologic response.This article summarizes and analyzes the studies on chronic hepatitis C patients who developed HCC after achieving sustained virologic response and identifies the risk factors for the development of HCC.It has been proved that some of the risk factors, such as male sex, age, liver cirrhosis, and diabetes, may be related to the development of HCC, but a lot of risk factors still await for further investigation.
- hepatitis C /
- chronic /
- sustained virologic response /
- carcinoma

HTML全文

参考文献(40)

[1]Chinese Socity of Hepatology and Chinese Society of Infection Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 updated[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[2]TOYODA H, TADA T, TACHI Y, et al.Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV[J].Antivir Ther, 2016.[Epub ahead of print]

[3]KOBAYASHI M, SUZUKI F, FUJIYAMA S, et al.Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection[J].J Med Virol, 2016.[Epub ahead of print]

[4]HEDENSTIERNA M, NANGARHARI A, WEILAND O, et al.Diabetes and cirrhosis are risk factors for hepatocellular carcinoma after successful treatment of chronic hepatitis C[J].Clin Infect Dis, 2016, 63 (6) :723-729.

[5]YANG JD, AHMED MOHAMMED H, CVINAR JL, et al.Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis C cirrhosis[J].Am J Gastroenterol, 2016.[Epub ahead of print]

[6]WU CK, CHANG KC, HUNG CH, et al.Dynamicα-fetoprotein, platelets and AST-to-platelet ratio index predict hepatocellular carcinoma in chronic hepatitis C patients with sustained virological response after antiviral therapy[J].J Antimicrob Chemother, 2016, 71 (7) :1943-1947.

[7]NAGAOKI Y, AIKATA H, NAKANO N, et al.Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy:a large-scale, long-term cohort study[J].J Gastroenterol Hepatol, 2016, 31 (5) :1009-1015.

[8]WU CK, CHANG KC, TSENG PL, et al.Comparison of therapeutic response and clinical outcome between HCV patients with normal and abnormal alanine transaminase levels[J].PLoS One, 2016, 11 (3) :e0142378.

[9]TOYODA H, KUMADA T, TADA T, et al.Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection[J].J Gastroenterol Hepatol, 2015, 30 (7) :1183-1189.

[10]QU LS, CHEN H, KUAI XL, et al.Effects of interferon therapy on development of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis:a meta-analysis of randomized controlled trials[J].Hepatol Res, 2012, 42 (8) :782-789.

[11]WATANABE S, ENOMOTO N, KOIKE K, et al.Cancer preventive effect of pegylated interferonα-2b plus ribavirin in a real-life clinical setting in Japan:PERFECT interim analysis[J].Hepatol Res, 2011, 41 (10) :955-964.

[12]KANOGAWA N, OGASAWARA S, CHIBA T, et al.Sustained virologic response achieved after curative treatment of hepatitis C virus-related hepatocellular carcinoma as an independent prognostic factor[J].J Gastroenterol Hepatol, 2015, 30 (7) :1197-1204.

[13]D'AMBROSIO R, DELLA CORTE C, COLOMBO M.Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy[J].Int J Mol Sci, 2015, 16 (8) :19698-19712.

[14]ALEMAN S, RAHBIN N, WEILAND O, et al.A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis[J].Clin Infect Dis, 2013, 57 (2) :230-236.

[15]YOUNOSSI ZM, STEPANOVA M, NADER F, et al.Associations of chronic hepatitis C with metabolic and cardiac outcomes[J].Alimen Pharmacol Ther, 2013, 37 (6) :647-652.

[16]ELKRIEF L, CHOUINARD P, BENDERSKY N, et al.Diabetes mellitus is an independent prognostic factor for major liver-related outcomes in patients with cirrhosis and chronic hepatitis C[J].Hepatology, 2014, 60 (3) :823-831.

[17]CHANG KC, HUNG CH, LU SN, et al.A novel predictive score fo hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy[J].J Antimicrob Chemother, 2012, 67 (11) :2766-2772.

[18]LEE MH, YANG HI, LU SN, et al.Hepatitis C virus genotype 1b increases cumulative lifetime risk of hepatocellular carcinoma[J].Int J Cancer, 2014, 135 (5) :1119-1126.

[19]KANWAL F, KRAMER JR, ILYAS J, et al.HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S.Veterans with HCV[J].Hepatology, 2014, 60 (1) :98-105.

[20]SHINDOH J, HASEGAWA K, TAKEMURA N, et al.Hepatitis Cviral load predicts tumor recurrence after curative resection of hepatocellular carcinoma regardless of the genotype of hepatitis C virus[J].Hepatol Int, 2014, 8 (1) :112-120.

[21]PINZONE MR, ZANGHìAM, RAPISARDA L, et al.Cirrhotic patients are still at risk of developing hepatocellular carcinoma despite Interferon-induced sustained virological response[J].Eur Rev Med Pharmacol Sci, 2014, 18 (2 Suppl) :11-15.

[22]CHEN J, HAN Y, XU C, et al.Effect of type 2 diabetes mellitus on the risk for hepatocellular carcinoma in chronic liver diseases:a meta-analysis of cohort studies[J].Eur J Cancer Prev, 2015, 24 (2) :89-99.

[23]TSUJITA E, MAEDA T, KAYASHIMA H, et al.Effect of sustained virological response to interferon therapy for hepatitis C to the hepatectomy for primary hepatocellular carcinoma[J].Hepatogastroenterology, 2015, 62 (137) :157-163.

[24]HUANG YW, WANG TC, YANG SS, et al.Increased risk of hepatocellular carcinoma in chronic hepatitis C patients with new onse diabetes:a nation-wide cohort study[J].Aliment Pharmacol T-her, 2015, 42 (7) :902-911.

[25]LI CI, CHEN HJ, LAI HC, et al.Hyperglycemia and chronic liver diseases on risk of hepatocellular carcinoma in Chinese patients with type 2 diabetes-National cohort of Taiwan Diabetes Study[J].In J Cancer, 2015, 36 (11) :2668-2679.

[26]OGAWA E, FURUSYO N, KAJIWARA E, et al.Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C:a prospective, multicenter study[J].J Hepatol, 2013, 58 (3) :495-501.

[27]HUANG CF, YEH ML, TSAI PC, et al.Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication[J].J Hepatol, 2014, 61 (1) :67-74.

[28]REDDY A, MAY E, EHRINPREIS M, et al.Latent hepatitis B is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C[J].World J Gastroenterol, 2013, 19 (48) :9328-9333.

[29]HUANG YW, YANG SS, FU SC, et al.Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with newonset diabetes:a nationwide cohort study[J].Hepatology, 2014, 60 (3) :807-814.

[30]HUNG CH, LEE CM, WANG JH, et al.Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis Cpatients treated with interferon-based antiviral therapy[J].Int JCancer, 2011, 128 (10) :2344-2352.

[31]KANEDA K, UENISHI T, TAKEMURA S, et al.The influence of postoperative glycemic control on recurrence after curative resection in diabetics with hepatitis C virus-related hepatocellular carcinoma[J].J Surg Oncol, 2012, 105 (6) :606-611.

[32]NKONTCHOU G, COSSON E, AOUT M, et al.Impact of metformin on the prognosis of cirrhosis induced by viral hepatitis C in diabetic patients[J].J Clin Endocrinol Metab, 2011, 96 (8) :2601-2608.

[33]KAWAGUCHI T, TANIGUCHI E, MORITA Y, et al.Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection[J].Liver Int, 2010, 30 (3) :479-486.

[34]HARRIS K, SMITH L.Safety and efficacy of metformin in patients with type 2 diabetes mellitus and chronic hepatitis C[J].Ann Pharmacother, 2013, 47 (10) :1348-1352.

[35]GOOSSENS N, NEGRO F.The impact of obesity and metabolic syndrome on chronic hepatitis C[J].Clin Liver Dis, 2014, 18 (1) :147-156.

[36]ADINOLFI LE, RESTIVO L, MARRONE A.The predictive value of steatosis in hepatitis C virus infection[J].Expert Rev Gastroenterol Hepatol, 2013, 7 (3) :205-213.

[37]ZAMPINO R, PISATURO MA, CIRILLO G, et al.Hepatocellular carcinoma in chronic HBV-HCV co-infection is correlated to fibrosis and disease duration[J].Ann Hepatol, 2015, 14 (1) :75-82.

[38]SARMA MP, ASIM M, MEDHI S, et al.Viral genotypes and associated risk factors of hepatocellular carcinoma in India[J].Cancer Biol Med, 2012, 9 (3) :172-181.

[39]HUNG CH, LU SN, WANG JH, et al.Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients[J].Antivir Ther, 2011, 16 (7) :959-968.

[40]MERCHANTE N, MERINO E, RODRGUEZ-ARRONDO F, et al.HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma[J].AIDS, 2014, 28 (1) :41-47.

施引文献

资源附件(0)

访问统计